- Home
- MBRX vs AIMD Comparison
MBRX vs AIMD Comparison
Compare MBRX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- AIMD
- Stock Information
- Founded
- MBRX 2015
- AIMD 1984
- Country
- MBRX United States
- AIMD United States
- Employees
- MBRX N/A
- AIMD N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- AIMD Health Care
- Exchange
- MBRX Nasdaq
- AIMD Nasdaq
- Market Cap
- MBRX 11.3M
- AIMD 9.9M
- IPO Year
- MBRX 2016
- AIMD N/A
- Fundamental
- Price
- MBRX $1.11
- AIMD $0.55
- Analyst Decision
- MBRX Strong Buy
- AIMD
- Analyst Count
- MBRX 2
- AIMD 0
- Target Price
- MBRX $6.00
- AIMD N/A
- AVG Volume (30 Days)
- MBRX 338.4K
- AIMD 198.1K
- Earning Date
- MBRX 05-09-2025
- AIMD 05-12-2025
- Dividend Yield
- MBRX N/A
- AIMD N/A
- EPS Growth
- MBRX N/A
- AIMD N/A
- EPS
- MBRX N/A
- AIMD N/A
- Revenue
- MBRX N/A
- AIMD $20,729.00
- Revenue This Year
- MBRX N/A
- AIMD N/A
- Revenue Next Year
- MBRX N/A
- AIMD N/A
- P/E Ratio
- MBRX N/A
- AIMD N/A
- Revenue Growth
- MBRX N/A
- AIMD N/A
- 52 Week Low
- MBRX $0.40
- AIMD $0.40
- 52 Week High
- MBRX $5.47
- AIMD $1.46
- Technical
- Relative Strength Index (RSI)
- MBRX 58.77
- AIMD 52.13
- Support Level
- MBRX $0.80
- AIMD $0.52
- Resistance Level
- MBRX $1.05
- AIMD $0.59
- Average True Range (ATR)
- MBRX 0.10
- AIMD 0.05
- MACD
- MBRX 0.04
- AIMD 0.00
- Stochastic Oscillator
- MBRX 100.00
- AIMD 50.00
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.